Liver transplantation is currently the only effective therapy for patients with fulminant hepatic failure. The availability of an artificial liver could bridge these patients through the relatively brief crisis period and allow their own livers to regenerate, providing a more favorable outcome and s
Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure
β Scribed by A J Ellis; R D Hughes; J A Wendon; J Dunne; P G Langley; J H Kelly; G T Gislason; N L Sussman; R Williams
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 202 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
of grade III encephalopathy and renal failure (serum creatinine
π SIMILAR VOLUMES
Older age is considered a poor prognostic factor in acute liver failure (ALF) and may still be considered a relative contraindication for liver transplantation for ALF. We aimed to evaluate the impact of older age, defined as age Υ 60 years, on outcomes in patients with ALF. One thousand one hundred
To compare the efficacy of a selective parenteral and enteral antimicrobial regimen in patients with fulminant liver failure, we classified 104 patients on reaching grade I1 encephalopathy as infected or noninfected. Patients who were infected were randomly assigned to receive IV cefuroxime (group 1
The pathophysiological basis of acute-on-chronic liver failure (ACLF) is unclear but systemic inflammatory response is thought to be important. In patients with ACLF, the molecular adsorbents recirculating system (MARS) improves individual organ function, but the effect of MARS on the proposed media